Novel capsid binder and PI4KIIIbeta inhibitors for EV-A71 replication inhibition
| Autor: | Jacob Westman, Gustav Arbrandt, Rachel Jia Wen Kooi, Yong Wah Tan, Wan Keat Yam, Justin Jang Hann Chu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Science 030106 microbiology Severe disease Disease Virus Replication Antiviral Agents Article 03 medical and health sciences Mice Capsid In vivo Virology Medicine Animals Enzyme Inhibitors Mild disease Multidisciplinary Foot-and-mouth disease business.industry Outbreak Enterovirus a71 medicine.disease Antivirals Phosphoric Monoester Hydrolases Enterovirus A Human 030104 developmental biology business |
| Zdroj: | Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021) Scientific Reports |
| ISSN: | 2045-2322 |
| Popis: | The Hand, Foot and Mouth Disease (HFMD) is a highly contagious viral illness generally manifests as a mild disease in young children and immunocompromised adults. It has however emerged as a significant public health threat in recent years as outbreaks have been occurring regularly, especially in the Asia–Pacific. The disease can result from infections by a wide variety of human enteroviruses, particularly, Enterovirus A71 (EV-A71) has garnered more attention due to its association with severe disease in infected patients. Despite the potential to result severe neurological complications or even fatality, there is currently no effective antiviral for treatment of EV-A71 infections and the only vaccines available are restricted to distribution in China. In this study, we report the in vitro and in vivo evaluation of two candidate antiviral compounds active against EV-A71, a viral capsid inhibitor (G197) and a novel host-targeting phosphatidylinositol 4-kinase III beta inhibitor (N373) which, especially when used in combination, can significantly improve the survival and pathology of infected mice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|